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Abstract KRAS mutations have been recognized as predic-
tive markers of primary resistance to anti-EGFR-antibodies in
colorectal cancer patients. In addition, newly detected KRAS
mutations have been reported to be related with acquired re-
sistance to chemotherapy containing anti-EGFR antibody.
Considering this evidence, monitoring of KRAS mutations is
indispensable for making treatment decisions, and the method
should be non-invasive allowing repeated examinations.
Recently, we established a novel automated sensitive detec-
tion system for KRASmutations, named mutation-biased PCR
quenching probe system (MBP-QP). The goal of our study
was to investigate the potential for monitoring KRAS
mutations during treatment with anti-EGFR antibodies. The
detection limit ofMBP-QP using a control plasmid containing
KRASmutations was 1–9 copies, and 0.05–0.3%mutant plas-
mid was detectable in a mixture of wild type and mutants.
One-hundred twenty colorectal cancer patients were geno-
typed for KRAS mutations with MBP-QP as well as polymer-
ase chain reaction reverse sequence-specific oligonucleotide
(PCR-rSSO), which has already been applied to cancer tissue
samples in the clinical setting. Concordance rates between
plasma DNA and cancer tissues were 68% with MBP-QP
and 66% with PCR-rSSO, indicating that these systems are
equivalent in terms of detecting KRAS mutations with plasma
DNA. KRAS mutations in plasma DNA were frequently ob-
served in systemic metastatic cancer patients, and in three
patients KRAS mutations appeared after chemotherapy con-
taining anti-EGFR antibody. A prospective study is needed
for clarifying whether KRAS mutations detected in plasma
DNA are predictive markers of treatment efficacy with anti-
EGFR antibody.
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Introduction
Treatment of metastatic colorectal cancer has progressed rap-
idly since molecular targeted therapy including anti-EGFR
monoclonal antibodies, such as cetuximab and panitumumab,
was introduced [1, 2]. Mutations of KRAS encoding a GTP-
binding protein that contributes to cell proliferation, angiogen-
esis, and tumor progression were detected in approximately
40% of colorectal cancers, and it has been reported to be
related with efficacy of treatment by anti-EGFR antibodies
[1–5]. Colorectal cancer patients with KRAS wild type
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respond better to anti-EGFR antibodies than patients with
KRASmutations, indicating that these mutations are predictive
markers for primary resistance to anti-EGFR-antibodies.
Recently, it has been recommended that KRAS and NRAS
mutations in exons 2, 3 and 4 be examined before treatment
with anti-EGFR antibodies, since these mutations are also
predictive markers [6, 7].
In addition to the relationship with primary resistance,
these mutations were also detected in patients who acquired
resistance to anti-EGFR antibodies [8–11]. Mechanisms of
acquired resistance to anti-EGFR antibodies include activa-
tion of an alternative pathway, such as MET/HGF or EGFR,
or activation of RAS/RAF/MAPK mediated through the ap-
pearance of KRASmutations [12–14]. Because the emergence
ofKRASmutations causes resistance to anti-EGFR antibodies,
detection of these mutations is indispensable for deciding sub-
sequent treatment. Although re-biopsy has been thought to be
the standard method for collection of cancer species, molecu-
lar alterations vary depending on the region of biopsy because
of tumor heterogeneity [15, 16]. Thus, we have focused on
circulating plasma DNA for monitoring KRAS mutations dur-
ing treatment with anti-EGFR antibodies.
We have newly established a fully-automated, sensitive
detection system for KRAS mutations using the mutation-
biased PCR and quenching probe (MBP-QP) method. The
method has already been applied to the detection of EGFR
mutations in lung cancer [17, 18]. Detection limits for
T790 M and L858R are 2 and 5 copies, and sensitivities are
0.3 and 0.2%, respectively. T790 M mutation was detected
with plasma DNA in 53% of lung adenocarcinoma patients
who acquired resistance to EGFR-TKI in our retrospective
study, and in 40% of those in a prospective, multi-
institutional study [17, 19]. The new detection system for
KRAS mutations used in this paper contained five types of
mutations in codon 12 as well as G13D, which together cover
98% of KRAS mutations in colorectal cancer [20, 21]. The
goal of our study was to investigate the potential for monitor-
ing KRAS mutations during treatment with anti-EGFR anti-
bodies. As the first step, we analyzed the concordance of
KRAS mutations between cancer tissue and plasma DNA,
and compared the result with PCR-rSSO, which has been
already applied in the clinic [22].
Materials and Methods
Cell Lines and Human Samples
Human cancer cell lines A549, H226B, Calu-1, SK-Lu-
1, HCT116, and RPMI8226 were purchased from the
American Type Culture Collection (Manassas, VA),
and RERF-LC-MT was kindly provided by Dr.
Tomonori Hayashi of the Radiation Effects Research
Foundation. These cells were cultured in RPMI-1640
supplemented with 10% fetal bovine serum at 37οC in
5% CO2. Tissue and patient-matched plasma samples
were obtained from 120 colorectal cancer patients who
underwent treatment at Saga Medical School Hospital,
the Cancer Institute Hospital of the Japanese Foundation
for Cancer Research, Saitama Medical Center, Jichi
Medical University, or Saga Prefectural Hospital between
2013 and 2015. The examination of KRAS mutation status in
primary lesions was performed using the TheraScreen®: K-
RAS Mutation Kit in the laboratories of SRL, Inc. (Tokyo,
Japan), and using the MEBGEN™ KRAS kit in the Cancer
Institute Hospital. The examination using TheraScreen®
contained seven different kinds of KRAS mutations, G12S,
G12C, G12R, G12D, G12 V, G12A, G13D, and that using
the MEBGEN™ KRAS kit contained twelve kinds of KRAS
mutations, G12S, G12C, G12R, G12D, G12 V, G12A, G13D,
G13S, G13C, G13R, G13 V, and G13A. Examination of
KRASmutations in cancer tissue was mostly performed before
the start of treatment. Pathological stage was determined ac-
cording to criteria of the 8th edition of the Japanese
Classification of Colorectal Carcinoma. The study protocol
was approved by each institute, and all patients gave informed
consent for obtaining surgical specimens according to the
Declaration of Helsinki.
Preparation of Control Plasmid and Analysis of KRAS
Mutations
The control plasmid was prepared as follows by GenScript
USA, Inc. A 320 bp DNA fragment (Accession No.
NG_007524, 10,380–10,699) was obtained by PCR, purified,
and subcloned into the pUC57 vector. Genomic DNA was
isolated from cancer cell lines using the QIAamp®DNAmini
kit (QIAGEN, Hilden, Germany) according to the manufac-
turer’s instructions. Peripheral blood samples from colorectal
cancer patients were collected into tubes containing 3.8%
citric acid, and plasma was immediately separated by
3000 rpm centrifugation at 4 °C for 20 min. DNAwas isolated
from 200 μl of patient plasma using a QIAamp® DNA mini
kit, as described previously [17–19]. KRAS mutations of co-
don 12/13 including G12A, G12C, G12D, G12S, G12 V, and
G13D were determined by the mutation-biased PCR and
quenching probe system (MBP-QP) using the fully automated
genotyping system i-densy™ IS-5320 (ARKRAY Inc.,
Kyoto, Japan) (Fig. 1). The MBP-QP method was already
established for detecting EGFR mutations T790 M and
L858R, as described previously [17–19]. In brief, the system
includes an MBP step, modified PCR, and a QP system for
detection using a TAMRA-conjugated, guanine-specific
quenching fluorophore probe (QProbe, J-Bio21, Tokyo,
Japan). The MBP-QP method covered 6 different KRAS mu-
tations: G12A, G12C, G12D, G12S, G12 V, and G13D.
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Criteria for declaring a sample mutation-positive were defined
by the areas under each mutation peak divided by that of the
wild type peak. Area under the peak was determined by the
Bidensy AreaAna®^ software (ARKRAY Incorporated,
Japan).KRASmutations with plasmaDNAwere also analyzed
by polymerase chain reaction reverse sequence-specific oligo-
nucleotide (PCR-rSSO), GENOSEARCH™ HS KRAS kit
(MEDICAL & BIOLOGICAL LABORATORIES CO.,
LTD., Nagano, Japan) using the Luminex® 100/200™ system
(Luminex Japan Corporation Ltd., Tokyo, Japan), which con-
tains a system for detecting thirteen differentKRASmutations:
G12S, G12C, G12R, G12D, G12 V, G12A, G13D, G13S,
G13C, G13R, G13 V, G13A and Q61H. Because the two
systems for detecting KRAS mutations in primary lesions,
the TheraScreen®: K-RAS Mutation Kit and the
MEBGEN™ KRAS kit, did not contain Q61H, data on
Q61H with plasma DNAwere excluded in the analysis com-
paring tissue and plasma DNA.
Statistical Analysis
Association between KRAS mutations in plasma DNA and
clinicopathological characteristics was analyzed using the
chi-square test for contingency tables. Statistical analyses
were conducted using IBM SPSS Statistics 22 (SPSS Inc.,
IBM Company).
Results
Detection Limits for KRASMutation
The detection limit of the MBP-QP method using con-
trol plasmids containing six types of KRAS mutations at
codon 12/13 was examined. The detection limits were
1–9 copies, and 0.05–0.3% mutant plasmid was detect-
able (Table 1). We also analyzed genomic DNA isolated
Mutant (G12V)< Mutation biased PCR >
Wild type
< QP-system >





























































































Fig. 1 a Principles of the MBP-
QP method. Figure 1a illustrates
the method in the case of KRAS
mutation G12 V. The MBP-QP
method consists of mutation-
biased PCR (MBP) and a
quenching probe (QP)-system. In
MBP, the difference in primer
lengths for wild type and mutant
sequences leads to a higher
efficiency of amplification of the
mutant sequence relative to that of
the wild type. Presence of KRAS
mutant amplicons is determined
by the QP-system using specific
guanine quench fluorophore
probe. Because the probe for wild
type is mismatched, melting
temperatures (Tm) differ,
resulting in the ability to
distinguish between wild-type
and mutant amplicons. b The
result with MBP-QP method
using genomic DNA isolated
from RERF-LC-MT (p. G12 V).
Areas under the curve of wild
type (A) and mutant (B) are
shown
KRAS mutations in plasma DNA
from six cancer cell lines in which the KRAS mutation
status was known. The detection limit was 0.02–0.04 ng
DNA (Table 1). When genomic DNA isolated from
H226B, which carries KRAS wild type, was combined
with those from the six cell lines having KRAS muta-
tions, 0.03–0.3% of mutants could be detected.
KRASMutations Were Detected with Plasma DNA
Isolated from Colorectal Cancer Patients
One hundred and twenty colorectal cancer patients were ex-
amined for KRAS mutation status with plasma DNA.
Characteristics of the patients are shown in Supplementary
Table S1. They comprised 56% with colon cancer and 44%
with rectal cancer. Most of the patients’ tumors were at stage
IV (60%) at the time of peripheral blood collection, and sam-
ple collection was conducted during chemotherapy in 82% of
the cases. Chemotherapy containing anti-EGFR antibody was
administered in 29 patients. KRAS mutations at codon 12/13
in cancer tissues were detected in 41% of the patients and
frequency of mutation types was similar to that reported in
the Catalogue of Somatic Mutations in Cancer (COSMIC)
database (20, 21). With plasma DNA, among patients in
whom KRAS mutations were positive in cancer tissue, KRAS
mutations were detected in 33% using MBP-QP and 33%
using PCR-rSSO (Table 2). Frequency of mutation type
G12D was higher, and G12 V was lower with MBP-QP than
with PCR-rSSO, which corresponds with results obtained
using control plasmid and genomic DNA isolated from cancer
cell lines. Among the patients with KRASwild type in primary
lesions, KRAS mutations were observed with plasma DNA in
two patients using MBP-QP and in one patient using PCR-
rSSO (Table 3). Concordance rates were 68% inMBP-QP and
66% in PCR-rSSO, indicating that these systems are equiva-
lent in terms of detecting KRAS mutations in plasma DNA.
The detection rate did not differ according to stage, mutation
type, or history of chemotherapy (Table 4). However, detec-
tion rate was significantly higher in the patients with metasta-
tic colorectal cancer involving three or more organs, although
the detection rate was 32% among entire patients with metas-
tasis. KRAS mutations tend to be less frequent in patients
during chemotherapy than in patients not treated with chemo-
therapy, although the difference was not statistically sig-
nificant. In addition, KRAS mutations were more frequent-
ly detected in plasma DNA among colon cancer patients




G12A 9 copy 0.05*
G12C 1 copy 0.05*
G12D 3 copy 0.10*
G12S 1 copy 0.10*
G12 V 8 copy 0.30*
G13D 2 copy 0.30*
Genomic DNA
G12A (RPMI8226) 0.02 ng 0.10†
G12C (Calu-1) 0.04 ng 0.03†
G12D (SK-Lu-1) 0.02 ng 0.30†
G12S (A549) 0.02 ng 0.03†
G12 V (RERF-LC-MT) 0.04 ng 0.30†
G13D (HCT116) 0.02 ng 0.30†
* Percentage of control plasmids carrying KRAS mutations relative to the
amount of wild type plasmid in the mixture
† Percentage of genomic DNA isolated from RPMI8226, Calu-1, SK-Lu-
1, A549, RERF-LC-MT, or HCT116 in the mixture with that from
H226B (wild type)
MBP-QP, mutation biased PCR-quenching probe system
Table 2 Mutation analysis with plasma DNA
Plasma DNA
KRAS mutations in tissue MBP-QP PCR-rSSO
Total (n = 49) 16 (33%) 16 (33%)
Mutation type, no. (%)
G12A (n = 1) 0 0
G12C (n = 5) 2 (40%) 2 (40%)
G12D (n = 13) 5 (38%) 3 (23%)
G12R (n = 5) - 0 (0.0)
G12S (n = 1) 1 (100%) 1 (100%)
G12 V (n = 11) 3 (27%) 5 (45%)
G13D (n = 13) 5 (38%) 5 (38%)
MBP-QP, mutation biased PCR-quenching probe system;
PCR-rSSO, PCR-reverse sequence-specific oligonucleotide




KRAS Mutant WT Mutant WT NE
Tissue Mutant (n = 49) 14 35 15 34 0
Wild type (n = 67) 2 65 1 64 2
Total (n = 116) 16 100 16 98 2
MBP-QP, mutation biased PCR-quenching probe system;
PCR-rSSO, PCR-reverse sequence-specific oligonucleotide; WT, wild
type, NE, not evaluated
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than in rectal cancer patients, and the difference was sta-
tistically significant.
KRASMutations in Plasma DNA Appeared
after Treatment with Anti-EGFR Antibody
When KRAS mutation was not detected in cancer tissues, the
results in plasma DNA were consistent with those in cancer
tissues except for three patients (Table 3). The clinical courses
of these patients are shown in Fig. 2. KRAS was wild type in
cancer tissue before treatment in all three cases. After treat-
ment with chemotherapy including anti-EGFR antibody,
KRAS mutations G12D, G13D, and G12 V were detected in
plasma DNA of these three patients. Peripheral blood was
obtained after acquired resistance to chemotherapy containing
anti-EGFR antibody in all three patients.
Discussion
In this paper, we demonstrated that KRAS mutations are de-
tectable in plasma DNA using the MBP-QP method.
Detection rate and concordance with cancer tissues using
MBP-QP were equivalent to those obtained with PCR-rSSO,
which has been already applied to cancer tissue in the clinical
setting. KRASmutations were frequently detected in systemic
metastatic cancers, and these were newly detected after ac-
quired resistance to anti-EGFR antibody.
Recently, mutation analysis using peripheral blood—so-
called liquid biopsy—has been applied to colorectal cancer
[9, 10, 23–25]. In most published reports, quantitative PCR
and BEAMing were used for detection with plasma DNA.
Among colorectal cancer patients with KRASmutation detect-
























Fig. 2 Clinical courses of three colorectal cancer patients, all of whom
had wild type KRAS in cancer tissues at the time of diagnosis and were
treated with chemotherapy containing anti-EGFR antibody. Mutation sta-
tus of KRAS with plasma DNA was analyzed after the start of
chemotherapy using the MBP-QP and PCR-rSSO methods. White and
black arrows in BKRAS mutation in plasma DNA^ indicate the peaks for
KRAS wild type and mutant type, respectively
Table 4 Characteristics of patients with KRAS mutations detected in
plasma DNA analysis using MBP-QP among the patient with KRAS
mutations in tumor tissue
n = 44*
Characteristics No. P†
Detection with plasma DNA, no. (%) 14/44 (32)
Clinical stage, no. (%)




Mutation type, no. (%)




G12 V 3/11 (27)
G13D 4/13 (31)
Chemotherapy, no. (%)
Naive 4/8 (50) 0.22
During treatment 10/36 (28)
No. of organs with cancer involvement, no. (%)
< 3 4/25 (16) 0.01
≥ 3 10/19 (53)
* The cases with G12R detected in cancer tissues were excluded
†Exact p value based on the chi-squared test
MBP-QP, mutation biased PCR-quenching probe system
KRAS mutations in plasma DNA
plasma DNA in from 76% to 98% of cases using these detec-
tion methods [21, 23, 24]. According to results using digital
PCR, tumor derived DNAwas detected in more than 75% of
colorectal cancer patients, and the detection rate was equiva-
lent to advanced pancreas, ovarian, breast, and gastroesopha-
geal cancers [24]. KRAS mutations with plasma DNA are
sometimes detected even if KRAS mutations were not found
in cancer tissues [21]. Technology for mutation detection has
progressed recently, and the sensitivity has been reported to be
less than 0.01% with some methods. However, the relation-
ship between mutation detection and treatment efficacy has
not yet been elucidated. According to a recent report, quantity
ofKRASmutations in plasmawas significantly correlatedwith
efficacy of chemotherapy using cetuximab and irinotecan
[26]. A higher level of mutated KRAS in plasma detected by
quantitative PCR corresponded with a lower disease control
rate (DCR); patients with greater than the upper quartile (75%)
ofKRASmutation level had a DCR of 0%, whereas those with
less than the upper quartile had a DCR of 42%. These data
indicate that the anti-cancer effect of chemotherapy containing
anti-EGFR antibody is correlated with the mutant load.
The detection rate using MBP-QP was relatively low
compared to other detection systems previously reported
[21, 23, 24]. It seems to be related to the fact that
patients in our study included non-metastatic cancer pa-
tients, and sample collection was conducted during che-
motherapy in 2/3 of those patients. Due to the inclusion
of patients with a variety of clinical features, some clin-
ical characteristics related with detection of KRAS mu-
tations in plasma DNA could be observed. First, it was
frequently detected in systemic metastatic patients, espe-
cially those with involvement of three or more organs.
Second, the frequency was higher before treatment than
during chemotherapy. These results suggest that appear-
ance of tumor derived DNA in peripheral blood is re-
lated with tumor burden and tumor progression.
According to our previous paper, detection of tumor
derived DNA in plasma was associated with tumor bur-
den in an animal model with systemic metastasis [27].
The detection rate was also significantly associated with
metastasis. It seems reasonable to assume that shrinking
tumor volume, including metastatic lesions after chemo-
therapy, caused the disappearance of tumor-derived
DNA in peripheral blood. The rate of detection of
KRAS mutations in plasma among colon cancer patients
was significantly higher than among rectal cancers.
Considering that it has been reported that the outcome
of colon cancer is worse than that of rectal cancer, the
result would also seem to be associated with tumor
progression [28]. In addition, we confirmed that KRAS
mutations were newly detected after acquired resistance
to anti-EGFR antibody contained in chemotherapy, as
other papers have reported. Since the first report of a
patient with acquired resistance to cetuximab having
newly detected KRAS mutation in cancer tissue, several
papers have demonstrated acquired KRAS mutations, in-
cluding mutations detected in plasma [8, 10, 11]. The
mechanism of appearance of KRAS mutations after ac-
quired resistance to anti-EGFR antibody has been as-
sumed to be clonal selection from a minor population
of pre-existing mutations or novel spontaneous muta-
tions, but this mechanism has not been clarified.
The goal of our study was to investigate the potential
for monitoring KRAS mutations during treatment with
anti-EGFR antibodies. This system has a possibility to
become an alternative method when biopsy is difficult
to perform, as with recurrent cases demonstrating distant
metastases. Investigation of mechanisms of acquired re-
sistance to molecular targeted therapy would be the
most promising application of our system. As the first
step, we examined the sensitivity of our system and the
clinical characteristics of patients with tumor-derived
DNA. After improving the sensitivity of our system
and extending it to allow examination of other kinds
of mutations, including all three RAS genes, the next
step will be to investigate whether mutation detection
can facilitate making decisions regarding subsequent
treatment strategy. To solve that question, it is urgently
needed to proceed to conducting a prospective study
investigating the relationship between the anti-cancer ef-
fect of chemotherapy containing anti-EGFR antibody
and the detection of KRAS mutations with plasma DNA.
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